Stackline and Redslim Partner to Deliver Unparalleled Retail Intelligence and Data Integration for Global Brands
Stackline, the leader in retail intelligence and data-driven commerce solutions, has announced a strategic partnership with Redslim, a leading data management company specializing in optimizing syndicated market data. This collaboration provides global CPG and CHC brands with a high-fidelity, 360-degree view of category performance—equipping them to make smarter, faster decisions in an increasingly competitive marketplace.
Stackline’s industry-leading solutions provide brands and manufacturers with deep, data-driven insights into category performance. By tracking sales volume, traffic, and conversion rates across the world’s top retail ecosystems, including Amazon, Stackline enables brands to decode the omnichannel shopper journey with precision. Its digital shelf solution delivers advanced analytics to optimize product listings, enhance digital shelf performance, and drive sustained ecommerce growth.
Redslim specializes in transforming fragmented market measurement data into harmonized, ready-to-use datasets. By integrating siloed data sources into centralized analytics systems, Redslim enables businesses to unlock actionable insights on market share, marketing effectiveness, and innovation strategies. This holistic approach ensures brands can leverage their data as a strategic asset, enabling smarter decisions and sustained competitive advantage.
This partnership between Stackline and Redslim fundamentally reshapes how brands harness data, seamlessly integrating Stackline’s intelligence into centralized analytics ecosystems. By unifying online and offline data, brands gain a comprehensive, end-to-end solution for optimizing performance and driving growth. With coverage across North America, Europe, and Asia—where a single marketplace can account for up to 20% of total market share—this collaboration delivers unparalleled visibility into online and omnichannel dynamics.
“Our partnership with Redslim strengthens our ability to deliver unmatched data access and actionable insights,” said Mitch Keidan, Vice President of Strategic Partnerships at Stackline. “By embedding Stackline’s intelligence into Redslim’s systems, we’re unlocking new ways for brands to maximize their data’s potential and fuel smarter, faster decisions.”
Marta Battiston, Chief Strategy Officer at Redslim, added, “By integrating Redslim’s harmonized syndicated market data with Stackline’s omnichannel and retail intelligence, we’re bridging critical data gaps and empowering brands with a truly comprehensive solution for strategic decision-making.”
As digital commerce continues to evolve, the ability to synthesize and interpret ecommerce and omnichannel data is more crucial than ever. Together, Stackline and Redslim are delivering an all-encompassing solution that enables brands to access harmonized market data, gain deeper ecommerce insights, and achieve a holistic view of market performance and competitive intelligence.
About Redslim
Redslim streamlines data management for teams faced with the request to leverage fragmented datasets for critical decision-making. Specialized in data engineering, harmonization, and BI, their teams manage data from over 50 agencies and cover more than 55 countries. Their technology-enabled services optimize data consumption for more than 30 global organizations. Active for more than 10 years, Redslim has constantly innovated their solutions to always meet the evolving needs of their clients and data partners. Learn more at www.redslim.net and follow Redslim on LinkedIn.
About Stackline
On a mission to fuel the future of commerce by bringing brands and customers closer together, Stackline is the leading AI-enabled retail intelligence and activation platform for the world's most innovative brands. Business leaders, product innovators, performance marketers, and financial firms trust Stackline as the single source of commerce truth. Fueled by proprietary neural networks and deep learning systems, Stackline's market insights, revenue metrics, behavioral data, and autonomous functionality create the actions that determine success or failure. Founded in 2014 in Seattle, Stackline employs over 250 connected commerce professionals creating value for 7,000 global brands.
Learn more by visiting https://www.stackline.com/partners or contact media@stackline.com. Follow Stackline on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319045474/en/
Contacts
media@stackline.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom